Brokerages expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to announce ($0.16) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for AMAG Pharmaceuticals’ earnings, with estimates ranging from ($0.21) to ($0.10). AMAG Pharmaceuticals reported earnings of $0.04 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 500%. The business is expected to report its next earnings report on Thursday, August 2nd.
According to Zacks, analysts expect that AMAG Pharmaceuticals will report full-year earnings of ($3.71) per share for the current financial year, with EPS estimates ranging from ($4.31) to ($3.10). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.40) per share, with EPS estimates ranging from ($4.65) to ($1.01). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, May 3rd. The specialty pharmaceutical company reported ($1.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($1.10). AMAG Pharmaceuticals had a negative net margin of 35.17% and a negative return on equity of 1.15%. The business had revenue of $146.40 million during the quarter, compared to analysts’ expectations of $149.13 million. During the same quarter last year, the business posted ($1.06) earnings per share. The company’s quarterly revenue was up 4.9% compared to the same quarter last year.
AMAG has been the subject of a number of research analyst reports. B. Riley increased their price target on AMAG Pharmaceuticals from $16.00 to $23.00 and gave the company a “neutral” rating in a research note on Wednesday, March 14th. Morgan Stanley increased their price target on AMAG Pharmaceuticals from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. BidaskClub upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, April 6th. Piper Jaffray Companies reiterated a “hold” rating and issued a $20.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, March 1st. Finally, Jefferies Financial Group cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the company from $21.00 to $20.00 in a research note on Monday, March 5th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $22.70.
AMAG Pharmaceuticals traded up $0.35, reaching $20.25, during midday trading on Friday, MarketBeat Ratings reports. The company’s stock had a trading volume of 985,658 shares, compared to its average volume of 928,376. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.48 and a current ratio of 1.57. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $25.63. The stock has a market cap of $701.98 million, a PE ratio of -3.55 and a beta of 0.20.
In other news, CEO William K. Heiden sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $25.00, for a total value of $500,000.00. Following the completion of the transaction, the chief executive officer now directly owns 333,015 shares in the company, valued at $8,325,375. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.00% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp raised its stake in shares of AMAG Pharmaceuticals by 31.2% in the first quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 65,600 shares of the specialty pharmaceutical company’s stock worth $1,322,000 after purchasing an additional 15,600 shares during the last quarter. Foundry Partners LLC purchased a new position in shares of AMAG Pharmaceuticals in the first quarter worth about $4,852,000. Voce Capital Management LLC raised its stake in shares of AMAG Pharmaceuticals by 15.9% in the first quarter. Voce Capital Management LLC now owns 182,122 shares of the specialty pharmaceutical company’s stock worth $3,670,000 after purchasing an additional 24,976 shares during the last quarter. LPL Financial LLC purchased a new position in shares of AMAG Pharmaceuticals in the first quarter worth about $692,000. Finally, Sei Investments Co. raised its stake in shares of AMAG Pharmaceuticals by 83.0% in the first quarter. Sei Investments Co. now owns 28,209 shares of the specialty pharmaceutical company’s stock worth $568,000 after purchasing an additional 12,793 shares during the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.